A phase I dose escalation study of BIBW 2992, an irreversible dual inhibitor of epidermal growth factor receptor 1 (EGFR) and 2 (HER2) tyrosine kinase in a 2-week on, 2-week off schedule in patients with advanced solid tumours (Q24653999)
Jump to navigation
Jump to search
scientific article published on 15 January 2008
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | A phase I dose escalation study of BIBW 2992, an irreversible dual inhibitor of epidermal growth factor receptor 1 (EGFR) and 2 (HER2) tyrosine kinase in a 2-week on, 2-week off schedule in patients with advanced solid tumours |
scientific article published on 15 January 2008 |
Statements
A phase I dose escalation study of BIBW 2992, an irreversible dual inhibitor of epidermal growth factor receptor 1 (EGFR) and 2 (HER2) tyrosine kinase in a 2-week on, 2-week off schedule in patients with advanced solid tumours (English)
F A L M Eskens
C H Mom
A S T Planting
A Amelsberg
H Huisman
L van Doorn
H Burger
P Stopfer
20 November 2007
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
Identifiers
2 references
2 references
2 references